☆ 4.5 Article

Evolution of teriflunomide use in multiple sclerosis: A real-world experience

JOURNAL OF THE NEUROLOGICAL SCIENCES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

Maria Pia Sormani et al.

Summary: This study compares the outcomes of COVID-19 in patients with multiple sclerosis (MS) in Italy with the expected outcomes in the general population. The risk of severe events, including hospitalization, ICU admission, and death, was found to be twice as high in the MS cohort compared to the age- and sex-matched Italian population. The increased risk was primarily associated with disease severity and comorbidities, but there was also a higher risk of hospitalization in patients on anti-CD20 therapies and a lower risk in patients on interferon.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)

添加到收藏夹

Article Environmental Sciences

Adherence to Therapy in Patients with Multiple Sclerosis-Review

Aleksandra Koltuniuk et al.

Summary: Multiple sclerosis is an incurable autoimmune disease of the central nervous system. Disease-modifying therapies aim to slow disease progression and improve patient's quality of life. Adherence to treatment is crucial for successful outcomes, as non-adherence can lead to treatment failure, increased relapse risk, and higher healthcare costs.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)

添加到收藏夹

Review Clinical Neurology

Smouldering multiple sclerosis: the 'real MS'

Gavin Giovannoni et al.

Summary: This article challenges the view that multiple sclerosis is purely an inflammatory disease and proposes a more comprehensive pathological process. It also emphasizes the importance of considering systemic disease processes in the management of multiple sclerosis.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2022)

添加到收藏夹

Review Clinical Neurology

An updated review of teriflunomide's use in multiple sclerosis

Aaron E. Miller

Summary: Teriflunomide, an oral daily disease-modifying therapy, has shown consistent efficacy and safety in patients with multiple sclerosis. Studies indicate positive effects on brain volume and potential antiviral effects. Patients generally report stable cognition and quality of life with no exacerbation of fatigue or disability. Recently approved for use in pediatric patients in the EU.

NEURODEGENERATIVE DISEASE MANAGEMENT (2021)

添加到收藏夹

Article Clinical Neurology

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria P. Sormani et al.

Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.

ANNALS OF NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study

Sebastiano Bucello et al.

Summary: Baseline factors associated with disease activity in patients with RRMS under teriflunomide treatment were identified in this study, with the most important factor being an EDSS > 4.0. The study suggests a place-in-therapy for teriflunomide in naive patients with mild disability level or in those who switched their initial treatment for poor tolerability. Adverse events related with teriflunomide were consistent with literature data, without any new safety concern.

JOURNAL OF NEUROLOGY (2021)

添加到收藏夹

Article Pediatrics

Teriflunomide: Pediatric First Approval

Julia Paik

Summary: Teriflunomide is an oral immunomodulatory agent developed by Sanofi for treating multiple sclerosis, and recently received approval in the EU for pediatric patients aged >= 10 years. This marks a significant milestone in the development of teriflunomide for relapsing-remitting MS in children.

PEDIATRIC DRUGS (2021)

添加到收藏夹

Article Clinical Neurology

First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study

Giorgia T. Maniscalco et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

添加到收藏夹

Article Clinical Neurology

COVID-19 in teriflunomide-treated patients with multiple sclerosis

Amir Hadi Maghzi et al.

JOURNAL OF NEUROLOGY (2020)

添加到收藏夹

Article Clinical Neurology

Silent progression in disease activity-free relapsing multiple sclerosis

Bruce A. C. Cree et al.

ANNALS OF NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis

Robert Zivadinov et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)

添加到收藏夹

Letter Clinical Neurology

Towards personalized therapy for multiple sclerosis: limitations of observational data

Ewout W. Steyerberg et al.

BRAIN (2018)

添加到收藏夹

Article Clinical Neurology

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

Alan J. Thompson et al.

LANCET NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry

Stefan Braune et al.

JOURNAL OF NEUROLOGY (2018)

添加到收藏夹

Review Clinical Neurology

No evident disease activity: The use of combined assessments in the management of patients with multiple sclerosis

Gavin Giovannoni et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

添加到收藏夹

Review Clinical Neurology

No evident disease activity: The use of combined assessments in the management of patients with multiple sclerosis

Gavin Giovannoni et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

添加到收藏夹

Article Clinical Neurology

Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study

Patricia K. Coyle et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)

添加到收藏夹

Article Clinical Neurology

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments

Ann Marie Weideman et al.

FRONTIERS IN NEUROLOGY (2017)

添加到收藏夹

Article Clinical Neurology

Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study

Emanuele D'Amico et al.

JOURNAL OF NEUROLOGY (2016)

添加到收藏夹

Review Clinical Neurology

Optimizing therapy early in multiple sclerosis: An evidence-based view

Tjalf Ziemssen et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)

添加到收藏夹

Article Clinical Neurology

Influence of treatments in multiple sclerosis disability: A cohort study

Eleonora Cocco et al.

MULTIPLE SCLEROSIS JOURNAL (2015)

添加到收藏夹

Review Pharmacology & Pharmacy

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis

Amit Bar-Or et al.

DRUGS (2014)

添加到收藏夹

Review Clinical Neurology

Defining the clinical course of multiple sclerosis The 2013 revisions

Fred D. Lublin et al.

NEUROLOGY (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis

Maria Trojano et al.

PLOS ONE (2012)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.